Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

Research and Innovation Action · Running

HERMOD Phase IIa Double-Blind, Placebo- Controlled, Randomized, Efficacy and Safety Study of Subcutaneously Administered HER-096 in Patients with Early-Stage Parkinson’s Disease HERMOD

Coordinator
Region Stockholm, Sweden
Runs
1 June 2026 to 31 May 2030
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
5 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101286586

What the project is doing

In the project's own words, from its summary on CORDIS.

The proposal aims to evaluate the efficacy and safety of HER-096 in treating Parkinson's disease (PD) through a multicentre, double-blind, placebo-controlled Phase IIa trial. HER-096 represents a visionary breakthrough in the treatment of PD, addressing the critical unmet need for a disease-modifying therapy. Engineered as a synthetic peptidomimetic derivative of cerebral dopamine neurotrophic factor (CDNF), HER-096 is designed to cross the blood-brain barrier, enabling non-invasive, outpatient or home-based dosing.

This innovative approach targets the unfolded protein response (UPR) pathway, reducing endoplasmic reticulum (ER) stress, neuroinflammation, and toxic α-synuclein aggregation, which are key pathological processes in PD. Phase I clinical trials have demonstrated the safety, blood-brain barrier penetrance, and pharmacokinetics of HER-096 in humans, supporting further clinical development. Building on these promising results, we are now advancing to a proof-of-concept (PoC) Phase IIa study together with leading European clinical centers in PD research.

This trial will evaluate the efficacy and safety of HER-096 in 75 early PD patients over a 26-week period. The primary endpoint is the delayed symptomatic effect of HER-096, assessed by a digital bradykinesia score. Secondary endpoints include the evaluation of disease progression, analysis of selected imaging and fluid biomarkers, and assessment of safety and tolerability. A key highlight of this study is the incorporation of digital health technologies (DHTs) for continuous, real-world monitoring of motor function.

Continuous monitoring provides a more sensitive assessment of motor symptoms than UPDRS, enabling smaller, shorter, and more cost-efficient trials while reducing the risk of false-negative outcome. By combining clinical, digital, and imaging innovation, this study aims to generate robust, actionable evidence for HER-096's potential as a disease-modifying therapy in Parkinson's disease.

Topics

Who is involved

OrganisationCityCountryRole
Region StockholmStockholmSwedenCoordinator
Herantis Pharma OyjEspooFinlandParticipant
Luxembourg Institute of HealthStrassenLuxembourgParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region SkaneKristianstadSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI